A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 801-806

  Montaner, Julio S G ^a   Zala, Carlos ^a   Conway, Brian ^a   Raboud, Janet ^a   Patenaude, Pierre ^a   Rae, Sandra ^a   O'Shaughnessy, Michael V ^a   Schechter, Martin T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL;

EID: 0030956535     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513974     Document Type: Article

References (23)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double blind, placebo-controlled trial. N Engl J Med 1987;317: 185-91.
2. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990;322:941-9.
3. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 1992;327:581-7.
4. 3. Ann Intern Med 1995;123:561-71.
5. Hammer SM, Katzenstein DA, Hughes MD, Hirsch MS, Merigan TC, ACTG 175 Virology Substudy Team. Virologic markers and outcome in ACTG 175 [abstract S24]. In: Proceedings of the 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC: Infectious Diseases Society of America, 1996:175.
6. Yeni P. Preliminary results of the European/Australian Delta trial: based on data up to 31st May, 1995 [abstract]. Presented at: Fifth European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, September 1995.
7. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90: 8925-8.
8. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994;266:801-5.
9. Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
10. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-21.
11. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19(suppl 9):11-19.
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:1317-22.
13. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
14. Raboud JM, Montaner JSG, Conway B, et al. Variation of plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996;174: 191-4.
15. Clotet B, Ruiz L, Cabrera C, et al. Short term anti HIV activity, at three month interval, of the combination of didanosine and hydroxyurea. Antiviral Res 1996;1:189-93.
16. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxyurate compounds. Lancet 1994;343:1292.
17. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:36-40.
18. Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996;174:204-9.
19. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994;121:263-8.
20. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995;9:159-63.
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
22. Hambleton J. Hematologic manifestations of HIV infection. In: Sande MA, Volberding PA, eds. The medical management of AIDS. 4th ed. Philadelphia: WB Saunders, 1995:318-31.
23. Consensus statement. Antiretroviral therapy for HIV infection in 1996. Recommendations of an International Panel. JAMA 1996;276:146-54.